Recently, Heczey et al., [120] reported interim results from three patients with relapsed or resistant neuroblastoma, who enrolled into the Phase I dose escalation trial, receiving dose Level 1 of autologous NKT cells coexpressing GD2 CAR and interleukin-15 (NCT03294954). Here, IL15 is linked to neuroblastoma.